<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005312</url>
  </required_header>
  <id_info>
    <org_study_id>C4671010</org_study_id>
    <nct_id>NCT05005312</nct_id>
  </id_info>
  <brief_title>Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332</brief_title>
  <official_title>A PHASE 1, NON-RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-07321332 BOOSTED WITH RITONAVIR IN ADULT PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY PARTICIPANTS WITH NORMAL HEPATIC FUNCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to estimate the effect of hepatic impairment on the plasma PK of&#xD;
      PF-07321332/ritonavir. Findings from this study will be used to develop dosing&#xD;
      recommendations so that the dose and/or dosing interval may be adjusted appropriately in the&#xD;
      presence of hepatic impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">December 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for PF-07321332</measure>
    <time_frame>0 (pre-dose) to 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Last Measurable Time (AUClast) for PF-07321332</measure>
    <time_frame>0 (pre-dose) up to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07321332</measure>
    <time_frame>0 (pre-dose) up to 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>Day 1 to 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Abnormal ECGs</measure>
    <time_frame>Day 1 to 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Abnormal Vital Signs</measure>
    <time_frame>Day 1 to 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Abnormal Laboratory Values</measure>
    <time_frame>Day 1 to 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic Impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07321332</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>PK Boosting agent</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants who are classically healthy having no clinically relevant&#xD;
             abnormalities. No known or suspected hepatic impairment&#xD;
&#xD;
          -  Stable hepatic impairment that meets the criteria for Class B of the Child-Pugh&#xD;
             Classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, prior bariatric surgery,&#xD;
             gastrectomy, ileal resection).&#xD;
&#xD;
          -  Participants who have been vaccinated with COVID-19 vaccines within the past week of&#xD;
             dosing&#xD;
&#xD;
          -  A positive urine drug test, for illicit drugs, at Screening&#xD;
&#xD;
          -  History of sensitivity reactions to ritonavir or any of the formulation components of&#xD;
             PF-07321332 or ritonavir.&#xD;
&#xD;
          -  eGFR &lt;60 mL/min/1.73m2 based on the Chronic Kidney Disease-Epidemiology Collaboration&#xD;
             (CKD-EPI) equation&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥ upper limit&#xD;
             of normal (ULN) (for healthy participants); AST or ALT &gt; 5x ULN (for hepatic&#xD;
             impairment participants)&#xD;
&#xD;
          -  Albumin &gt; ULN (for healthy participants);&#xD;
&#xD;
          -  Prothrombin time &gt; ULN (for healthy participants);&#xD;
&#xD;
          -  Total bilirubin level ≥1.5 × ULN [NOTE: Participants with a history of Gilbert&#xD;
             syndrome (and hence elevated total bilirubin) are eligible provided direct bilirubin&#xD;
             level is ≤ ULN).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prism Research LLC dba Nucleus Network</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4671010</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

